| [1] |
WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi.
Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model
[J]. China Oncology, 2024, 34(9): 873-880.
|
| [2] |
XIAO Feng, XU Tonglin, ZHU Lin, XIAO Jingwen, WU Tianqi, GU Chunyan.
Significance of infiltration of M1 tumor-associated macrophages in hepatocellular carcinoma
[J]. China Oncology, 2024, 34(8): 726-733.
|
| [3] |
Cancer Assessment Society of China Anti-Cancer Association, Cancer Pain Society of Fujian Anti-Cancer Association.
Chinese expert consensus on whole-process management of oxaliplatin-induced hypersensitivity reactions (2024 edition)
[J]. China Oncology, 2024, 34(8): 785-805.
|
| [4] |
LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei.
An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy
[J]. China Oncology, 2024, 34(7): 659-668.
|
| [5] |
CHEN Hong, CAO Zhiyun.
Recent progress in the construction and application of patient-derived pancreatic cancer organoid models
[J]. China Oncology, 2024, 34(6): 590-597.
|
| [6] |
Urologic Chinese Oncology Group.
Expert consensus on early diagnosis and treatment of bladder cancer (2024 edition)
[J]. China Oncology, 2024, 34(6): 607-618.
|
| [7] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
| [8] |
Professional Committee on Gastric Cancer of Shanghai Anticancer Association , Professional Committee on Gastrointestinal Cancer of China Association for Promotion of Health Science and Technology .
Chinese expert consensus on clinical practice of locally advanced gastric cancer invading adjacent organs (2024 edition)
[J]. China Oncology, 2024, 34(5): 517-526.
|
| [9] |
FENG Zheng, GUO Qinhao, ZHU Jun, WU Xiaohua, WEN Hao.
Progress in treatment of gynecological cancer in 2023
[J]. China Oncology, 2024, 34(4): 340-360.
|
| [10] |
XU Yonghu, XU Dazhi.
Progress and prospects of gastric cancer treatment in the 21st century
[J]. China Oncology, 2024, 34(3): 239-249.
|
| [11] |
WANG Xuefei, ZHOU Peng, TANG Zhaoqing.
New progress and development trend of surgical treatment for gastric cancer
[J]. China Oncology, 2024, 34(3): 250-258.
|
| [12] |
ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin.
“Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer
[J]. China Oncology, 2024, 34(11): 1045-1052.
|
| [13] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|
| [14] |
Colorectal Cancer Special Committee of Shanghai Anti-Cancer Association .
Shanghai plan for early screening, diagnosis and treatment of colorectal cancer (2023 edition)
[J]. China Oncology, 2024, 34(1): 13-66.
|
| [15] |
JIANG Lili, MA Yan, ZHANG Tiantian, HUANG Shan.
Clinical analysis of 21 cases of primary Ewing sarcoma of the thoracic wall
[J]. China Oncology, 2024, 34(1): 74-81.
|
